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acuole fusion requires a coordinated cascade of
priming, docking, and fusion. SNARE proteins have
been implicated in the fusion itself, although their
precise role in the cascade remains unclear. We now report
that the vacuolar SNAP-23 homologue Vam7p is a mobile
element of the SNARE complex, which moves from an initial
association with the cis-SNARE complex via a soluble
intermediate to the docking site. Soluble Vam7p is specifically
recruited to vacuoles and can rescue a fusion reaction
V
 
poisoned with antibodies to Vam7p. Both the recombinant
Vam7p PX domain and a FYVE domain construct of human
Hrs block the recruitment of Vam7p and vacuole fusion,
demonstrating that phosphatidylinositol 3-phosphate is a
primary receptor of Vam7p on vacuoles. We propose that
the Vam7p cycle is linked to the availability of a lipid
domain on yeast vacuoles, which is essential for coordinating
the fusion reaction prior to and beyond docking.
 
Introduction
 
Membrane fusion along the secretory and endocytic path-
way is highly coordinated and is controlled by a variety of
proteins (Mellman and Warren, 2000). SNAREs are key
proteins in this process: they are found on vesicles and or-
ganelles, pair in a cognate fashion, and appear to act at the
center of the fusion process itself (for review see Rothman,
1994; Jahn and Südhof, 1999; Chen and Scheller, 2001).
SNAREs form cis complexes on membranes that are disas-
sembled through the action of NSF and 
 

 
-SNAP (Söllner et
al., 1993; Walch-Solimena et al., 1995; Otto et al., 1997;
Holthuis et al., 1998; Ungermann et al., 1998a). During the
fusion reaction, SNAREs from opposite membranes meet
in trans to drive the membranes into close apposition
(Ungermann et al., 1998b), presumably by forming a tight
four-helix bundle as proposed from the crystal structure
(Sutton et al., 1998). This complex is sufficient to drive
liposome fusion in vitro (Weber et al., 1998). In vivo the
situation is more complex. Assembly of trans-SNARE
complexes requires the action of specific Rab GTPases and
their effectors (Chen and Scheller, 2001; Zerial and Mc-
Bride, 2001). Rab proteins mediate the initial and reversible
contact of membranes by interacting with tethering factors
specifically in the GTP-bound form (Cao et al., 1998;
Ungermann et al., 1998b; Christoforidis et al., 1999a; Zerial
and McBride, 2001). The tethering factors are required
before SNARE action and may chaperone SNAREs to the
fusion site (McBride et al., 1999). Most tethering proteins
belong to multisubunit complexes and have no obvious
homology (Zerial and McBride, 2001), though they are
structurally related (Whyte and Munro, 2001). Phosphoino-
sitides are closely linked to some of the tethering proteins
(Sato et al., 2001; Simonsen et al., 2001). Vac1p and its
mammalian relatives EEA1 and rabenosyn-5 localize to the
endosome, in part by binding to phosphatidylinositol (PtdIns)*
3-phosphate (PtdIns 3-P) (Stenmark et al., 1996; Burd and
Emr, 1998; Kutateladze et al., 1999; Peterson et al., 1999;
Nielsen et al., 2000). Furthermore, the PtdIns 3-kinase
Vps34p is present in two different complexes, on the trans-
Golgi and on autophagosomes (Stack et al., 1995; Kihara et
al., 2001). In both cases, it appears that synthesis of PtdIns
3-P is a prerequisite that facilitates a fusion process by per-
mitting the recruitment of essential fusion factors.
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Figure 1. Priming-dependent release of Vam7p on ice. (A) Vam7p is released from the vacuoles in an ATP-dependent reaction. BJ3505 
vacuoles (12 g) were incubated in a 60-l reaction for 60 min on ice or at 26C in reaction buffer containing His6-Sec18p, CoA (10 M), 
and ATP as indicated. Then vacuoles were separated from the supernatant (5 min, 20,000 g, 4C), and the reaction supernatant was precipitated 
by addition of TCA (13% [vol/vol]) (Ungermann et al., 1998a). Vacuole pellets and precipitated proteins from the supernatant were solubilized 
in sample buffer and analyzed by SDS-PAGE and immunoblotting. Immunoblots were decorated with indicated antibodies. (B) Release of 
Vam7p and Sec17p on ice is immediate. BJ3505 vacuoles (12 g) were incubated on ice, separated into vacuole and supernatant fraction, 
and processed as in A. Immunoblots of the supernatant fractions were quantified and plotted versus time. The inset shows a quantification of 
Vam7p in the reaction supernatant after a 60-min incubation on ice or at 26C. (C) Priming inhibitors block Vam7p release. BJ3505 VAM7-HA 
vacuoles (12 g) were incubated in the presence of ATP and IgGs to Sec17p and Sec18p where indicated. Pellet and supernatant fractions 
were analyzed with HA antibodies to detect Vam7p. HA-tagged Vam7p was used to avoid interference with the added IgGs during immunoblot 
decoration. (D) Incubation with ATP on ice allows bypass of priming. BJ3505 and DKY6281 vacuoles (6 g) were incubated in the presence 
of ATP at the indicated temperature. Inhibitors (-Sec17p, -Sec18p [200 g/ml], -Vam3p [50 g/ml], and Gdi1p [300 g/ml]) were added 
to the reactions either right away (white bars), after a 30-min ice incubation (gray bars), or after a 30-min incubation at 26C. Each reaction 
was then incubated for an additional 60 min at 26C and then assayed for alkaline phosphatase activity. (E) Vam7p is released from the 
cis-SNARE complex. BJ3505 vacuoles (36 g) were incubated in a 180-l reaction on ice for 10 min. Vacuoles were reisolated (5 min, 
20,000 g, 4C) and solubilized in lysis buffer (150 mM KCl, 0.5% Triton X-100, 20 mM Hepes/KOH, pH 7.4, 1xPIC, and 1 mM PMSF) for 10 
min at 4C and centrifuged (20,000 g, 10 min, 4C). The soluble detergent extract was added to protein A–Sepharose–coupled antibodies to 
Vam3p (Ungermann et al., 1998a) and incubated for 2 h at 4C on a nutator. Reisolated beads were washed once with lysis buffer and once 
with lysis buffer containing 500 mM KCl. Bound proteins were eluted from the beads with 1 ml of 0.1 M glycine, pH 2.6. The eluate was TCA 
precipitated and analyzed by SDS-PAGE, Western transfer and immunoblotting with antibodies against the indicated proteins. (F) Released 
Vam7p is a monomer. BJ 3505 vacuoles (60 g) were incubated in the presence of ATP on ice or at 26C as described in the legend to Fig. 1 
A. The supernatant was loaded onto a continuous glycerol gradient (10–30% in PS buffer supplemented with 150 mM KCl). The samples 
were centrifuged at 40,000 rpm in a SW40 rotor for 18 h at 4C. Fifteen 500-l fractions were collected, TCA precipitated, and analyzed by 
SDS-PAGE and immunoblot as before.
 

 
-SNAP) disassemble the SNARE complex into its subunits,
and HOPS is released and associates with Ypt7p to initiate
tethering (Wickner and Haas, 2000). Docking also relies
on the action of two Rho GTPases, Cdc42p and Rho1p,
that act after Ypt7p (Eitzen et al., 2001; Müller et al.,
2001). Later, SNAREs from opposing vacuoles meet in
trans to drive the membranes in close apposition (Unger-
mann et al., 1998b). Fusion then depends on Ca
 
2
 

 
, cal-
modulin, protein phosphatase 1, and the proteolipid of the
vacuolar ATPase (Peters and Mayer, 1998; Peters et al.,
1999, 2001). Two lipid requirements have been reported.
PtdIns 4,5-bisphosphate and ergosterol, the yeast analogue
In vitro fusion of yeast vacuoles serves as a model system
to analyze the characteristics of a membrane fusion reac-
tion. Vacuole fusion occurs in a coordinated cascade of
priming, docking, and fusion (Wickner and Haas, 2000)
and depends on a SNAP-23 homologue, Vam7p (Unger-
mann and Wickner, 1998). On the isolated yeast vacuole,
Vam7p is part of the SNARE complex, which contains the
SNAREs Vam3p, Vti1p, Nyv1p, and Ykt6p (Sato et al.,
1998; Ungermann and Wickner, 1998; Ungermann et
al., 1999). The HOPS tethering complex and Vac8p are
also part of this complex (Price et al., 2000; Veit et al.,
2001). During priming, Sec17p and Sec18p (yeast NSF and
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of cholesterol, are required for priming and docking
(Mayer et al., 2000; Kato and Wickner, 2001), though
their mode of action remains to be discovered.
The role of Vam7p during vacuole fusion is the focus
of the present study. We showed previously that extrac-
tion of Ypt7p by Gdi1p caused a release of Vam7p to the
reaction supernatant, indicating that Vam7p is not firmly
anchored to the vacuole (Ungermann et al., 2000). In-
deed, Vam7p exists in pools in the cytosol and on the
vacuole membrane (Sato et al., 1998), quite similar to the
distribution of its homologue SNAP-23 between secre-
tory granules and the cytosol (Guo et al., 1998; Faigle et
al., 2000). The NH
 
2
 
-terminal PX domain of Vam7p has
been implicated in membrane binding via PtdIns 3-P
(Cheever et al., 2001). In the present study, we investi-
gated the mobility of Vam7p and the function of this
mobility for vacuole fusion. We demonstrate that Vam7p
cycles between the vacuole and the cytosol: Vam7p is re-
leased rapidly from the vacuole after priming and is re-
covered as a soluble factor in the cytosolic fraction, the
soluble protein is functional and can rescue vacuole fu-
sion, and Vam7p is recruited to the vacuole membrane
before fusion via the PX domain. The specific block of
vacuole fusion by exogenously added PX or FYVE do-
mains suggests that a PtdIns 3-P acceptor site on vacuoles
is essential for vacuole fusion.
 
Results
 
A soluble intermediate of Vam7p
 
After priming, Vam7p retention on the vacuole depends on
Ypt7p (Ungermann et al., 2000). This suggests that Vam7p
must be transferred from the cis complex to the tethering ma-
chinery. We asked if we could uncouple the transfer of Vam7p
by retarding the fusion reaction to characterize the mobility of
Vam7p in detail. We incubated isolated vacuoles in the pres-
ence of ATP either on ice or at 26
 

 
C (Fig. 1 A). Surprisingly, a
substantial fraction of Vam7p appeared in the reaction super-
natant during the ice incubation (Fig. 1 A, lane 2). Since
Sec17p was also observed in the supernatant, priming must
have occurred. Other SNARE-associated proteins, such as
Vac8p, were not released from the vacuole (Fig. 1 B). Much
less Vam7p was found in the supernatant at 26
 

 
C (Fig. 1 A,
lane 3). Our observations indicate that the released Vam7p be-
comes unstable at 26
 

 
C, whereas it is stable when released on
ice, though we do not yet know whether the degradation to a
shorter fragment (unpublished data) is a specific effect.
We then analyzed the kinetics of the release reaction.
About 50% of Vam7p and Sec17p were released from the
vacuole within 10 min after ATP addition, significantly
more Vam7p than was released if samples were incubated at
26
 

 
C (Fig. 1 B). The release of Vam7p on ice was specific.
Antibodies to Sec17p and Sec18p, both inhibitors of prim-
ing, blocked the release of Sec17p and Vam7p (Fig. 1 C; for
an overview of the inhibitors used see Fig. 7). Docking and
fusion inhibitors did not interfere with this reaction (unpub-
lished data). In addition, we added inhibitors to a fusion re-
action after the ice incubation. Fusion is measured by bio-
chemical complementation using two different types of
vacuoles (Conradt et al., 1992; Haas et al., 1994). Vacuoles
from one strain contain immature proalkaline phosphatase
because of the lack of proteases. The other set of vacuoles
contains proteases but lacks alkaline phosphatase. Fusion
and content mixing leads to processing and activation of al-
kaline phosphatase, which can be measured spectrophoto-
metrically (Haas et al., 1994). The fusion reaction had be-
come resistant to Sec17p and Sec18p antibodies during the
ice incubation (Fig. 1 D, gray bars). In contrast, the reaction
was still inhibited by antibodies to the t-SNARE Vam3p
that block docking, demonstrating that we uncoupled prim-
ing from docking (Fig. 1 D). Resistance to all inhibitors was
achieved after 30 min at 26
 

 
C (Fig. 1 D, black bars). The re-
leased Vam7p was indeed part of the SNARE complex be-
fore release (Fig. 1 E). Vam7p, and Nyv1p and Ykt6p were
isolated with Vam3p by coimmunoprecipitation and were
released efficiently from Vam3p, regardless of whether the
vacuoles were primed on ice or at 26
 

 
C (Fig. 1 E) (Unger-
mann and Wickner, 1998). In contrast, Vam3p remained
associated with Vti1p during the ice incubation and was re-
leased only if vacuoles were primed at 26
 

 
C (unpublished
data; Ungermann et al., 1999). Apparently, we are able to
resolve multiple steps in the priming reaction.
Since the released Vam7p was completely soluble in the
reaction supernatant, we analyzed it by glycerol gradient
centrifugation to determine its size. Vam7p, a 37-kD pro-
tein, migrated in the gradient at 40 kD (Fig. 1 F), implying
that Vam7p was not bound to other proteins while released. 
Thus, priming of vacuoles on ice uncouples priming from
docking and causes a significant release of monomeric
Vam7p from the vacuole.
 
The Vam7p cycle
 
If after priming Vam7p existed in equilibrium between the
soluble and the membrane-bound form, we would expect
that repeated removal of the supernatant during the ice/ATP
incubation should result in a complete removal of Vam7p.
This was indeed the case (Fig. 2 A). More than 90% of
Vam7p was released to the reaction supernatant when the
ice incubation was done repeatedly. We then asked if the
same treatment and the removal of Vam7p would also abol-
ish fusion (Fig. 2 B). Fusion activity was lost when a fresh re-
action mixture replaced the Vam7-containing supernatant
after the ice incubations (Fig. 1 D, white bars). However, fu-
sion was completely restored if the supernatant of the first
ice incubation was added back to the vacuole pellet (Fig. 1
D, white compared with black bars). Repeated centrifuga-
tion did not impair fusion activity (Fig. 1 D, gray bars). This
suggested that Vam7p could be a mobile fusion factor that is
recruited back to the vacuoles before fusion.
Therefore, we asked whether the released Vam7p was
functional in the vacuole fusion reaction (Fig. 2 C). Vac-
uoles from both tester strains were mixed and incubated
on ice to release Vam7p. Then IgGs to Vam7p were
added to the acceptor vacuoles to block the portion of
Vam7p that was still bound to the membrane (Fig. 2 C,
lanes 3–7). Thus, fusion should not occur, unless we pro-
vided the reaction with Vam7p. As expected, fusion was
blocked if antibodies to Vam7p were added after the ice
 82 The Journal of Cell Biology 
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incubation (Fig. 2 C, lane 4). For this analysis, we reiso-
lated the vacuoles, washed them briefly, and supplied
them with the supernatant from a parallel ice incubation
of either wild-type (Fig. 2 C, lane 5) or 
 
vam7
 

 
 vacuoles
(Fig. 2 C, lane 6), or fresh reaction mixture (Fig. 2 C,
lane 7). Then the reactions were shifted to 26
 

 
C and in-
cubated for 60 min before being assayed for fusion.
When new reaction mixture and reaction supernatant
from 
 
vam7
 

 
 vacuoles primed on ice in parallel were
added to the pretreated vacuoles, no fusion activity was
recovered (Fig. 2 C, lanes 6 and 7). However, the reac-
tion supernatant from wild-type vacuoles rescued the ac-
tivity (Fig. 2 C, lane 5). We confirmed this finding by a
different approach. When released Vam7p was depleted
from the supernatant by two specific antibodies, the su-
pernatant did not rescue the fusion of ice-primed vacu-
oles (Fig. 2 D), demonstrating that soluble Vam7p is a
functional intermediate in vacuole fusion.
We then asked at what stage soluble Vam7p could rescue fu-
sion. Vacuoles were pretreated on ice with ATP to release
Vam7p into the supernatant and then reisolated and incubated
with anti-Vam7p as before. The indicated inhibitors and the
Vam7p-containing supernatant were added to the reisolated
and washed vacuoles and were incubated to allow for fusion
(Fig. 2 E). Vacuoles became resistant to docking inhibitors
during the repeated reisolation procedure. However, they re-
mained sensitive to fusion inhibitors like BAPTA and MCLR
(Fig. 2 E) and dependent on the soluble Vam7p provided with
the reaction supernatant. Thus, Vam7p can rescue the reaction
at a stage when fusion is insensitive to docking inhibitors.
To establish a recruitment assay for Vam7p, we COOH-
terminally tagged Vam7p with a protein A affinity tag
(Vam7-A). The modified protein replaced the endogenous
protein and was completely functional in vacuole fusion
(unpublished data). We then performed our release assay
with vacuoles carrying either the wild-type or the tagged ver-
Figure 2. Released Vam7p is functional. (A) Complete Vam7p release during consecutive ice incubations. BJ3505 vacuoles (12 g) 
were incubated in the presence of ATP on ice. After 30 min, the reaction was centrifuged (5 min, 20,000 g, 4C), supernatant was 
removed, and a fresh reaction mix was added to the vacuoles. This procedure was repeated four times. The supernatant and the pellet 
were analyzed by immunoblotting with antibodies to Vam7p. Loss of Vam7p in the supernatant in the second reaction is due to the 
instability of released Vam7p (see text). (B) Removal of the supernatant coincides with loss of fusion activity. A fusion reaction containing the 
two tester strains was incubated as in A. After each incubation, vacuoles were reisolated (5 min, 20,000 g, 4C) and resuspended either 
in new reaction mix containing Sec18p and CoA (white bars), the same supernatant (gray bars) to monitor loss of fusion due to centrifugation, 
or in the Vam7-containing supernatant removed in the first incubation (black bars). All samples were then incubated for 60 min at 26C 
before assaying for fusion activity. (C) Fusion of vacuoles poisoned with anti-Vam7p. Fusion reactions containing both tester strains 
were incubated in a first incubation on ice or at 26C for 30 min. Vacuoles were then reisolated (20,000 g, 5 min, 4C), incubated for 5 
min with or without anti-Vam7p on ice, and reisolated. Supernatant of a parallel reaction (30 min on ice in the presence of ATP) containing 
wild-type vacuoles or vam7 vacuoles was added to the pretreated vacuoles, incubated for 60 min at 26C, and assayed for alkaline 
phosphatase activity. (D) Depletion of Vam7p from the supernatant blocks fusion. Priming on ice was done two times as described in 
A. The supernatant containing released Vam7p was incubated for 30 min at 4C with protein A–Sepharose containing nonimmune IgG, 
anti-Vam7 (1–122) (-PX), or anti-Vam7 (165–316) (-cc). Then, the cleared supernatant was added to primed vacuoles as in A. (E) Soluble 
Vam7p can rescue fusion at a stage that is insensitive to docking inhibitors. Inhibitors were added to a fusion reaction either from the 
beginning (white bars) or after pretreatment with anti-Vam7p (black bars) as described in C. Fusion reactions were then incubated for 
60 min at 26C, and fusion activity was determined.
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sion of Vam7p. After the ice incubation, vacuoles were sedi-
mented and washed briefly. Then wild-type vacuoles were
resuspended in supernatant from vacuoles with the tagged
Vam7p, and the reaction was shifted to 26
 

 
C. After 60 min,
the reaction was separated into vacuoles and reaction super-
natant, and both fractions were analyzed by Western blot-
ting. As seen in Fig. 3 A, Vam7-A is mobilized during the ice
incubation and a substantial fraction appears in the reaction
supernatant (lane 1). Upon incubation of the Vam7-A–con-
taining supernatant with the wild-type acceptor membrane,
Vam7-A is efficiently recruited to the vacuole membrane
(Fig. 3 A, lane 2). Similar results were obtained with an HA-
tagged version of Vam7p (Fig. 3 C). The rebinding of
Vam7-A to the acceptor vacuole is finished within 30 min
(Fig. 3 B). In contrast, Sec17p that was released in parallel
with Vam7p in the first incubation remained in the superna-
tant (unpublished data), suggesting that the recruitment of
Vam7p does not reflect the mere reformation of a cis-
SNARE complex.
We then analyzed whether inhibitors of the fusion reac-
tion interfere with the recruitment of Vam7p (Fig. 3 C). Be-
cause of the frequent instability of Vam7p in the superna-
tant, only the recruited fraction of Vam7p was used as a
read-out of the following experiments. After the incubation
with ATP on ice, the indicated inhibitors were added to the
reisolated vacuoles before resuspending them in the Vam7-
A–containing supernatant. Rebinding of Vam7-A was effi-
cient in the presence of fusion inhibitors (Fig. 3 C, lanes 2,
4, and 5). In contrast, addition of Gdi1p (Fig. 3 C, lane 3),
neomycin (Fig. 3 C, lane 6), or apyrase (Fig. 3 C, lane 7), all
of which block the docking step of vacuole fusion (Mayer et
al., 1996, 2000), prevented the retrieval of Vam7-A from
the supernatant completely. The characterized inhibitors
may therefore relate to a specific receptor of Vam7p. Inter-
estingly, when anti-Sec17p was added to the acceptor vacu-
oles before any pretreatment Vam7p binding was com-
pletely abolished (Fig. 3 D). Thus, priming is essential to
create a binding site for Vam7p.
We then analyzed whether any of the known fusion pro-
teins serves as an acceptor site for Vam7p on the vacuole. Nei-
ther IgGs to Vam3p, Nyv1p, Vam7p, Ypt7p, or Vam6p
added to acceptor vacuoles, nor the use of vacuoles from dele-
tion strains (
 
vam3
 

 
, 
 
vam7
 

 
, 
 
ypt7
 

 
, 
 
vam6
 

 
, 
 
vac8
 

 
, or
 
nyv1
 

 
) as acceptor membranes uncovered a clear binding site
Figure 3. Recruitment of soluble Vam7p to vacuoles. (A) Wild-type vacuoles (BJ3505) and Vam7-A vacuoles were incubated in the presence 
of ATP for 30 min on ice. Vacuoles were reisolated (20,000 g, 5 min, 4C), and wild-type vacuoles were resuspended in supernatant removed 
from Vam7-A vacuoles and incubated for 60 min at 26C. Then the reaction was centrifuged as before and analyzed for Vam7p in pellet (P) 
and supernatant (S). The second band in lane 1 is a degradation product of Vam7-A. (B) Time course of recruitment. Recruitment of Vam7-A 
to wild-type vacuoles was done as in A but for different time points. Immunoblots showing Vam7-A were quantified by densitometry and 
plotted. The total amount of Vam7p in the supernatant was set to 100%. (C) Gdi1p, ATP depletion by apyrase, and neomycin block Vam7p 
rebinding. Wild-type and Vam7-A vacuoles were preincubated as in A. The indicated inhibitors were added to the recruitment reaction at the 
following concentrations: BA, 2 mM BAPTA; Gdi, 300 g/ml Gdi1p; MC, 10 M microcystin LR; S, 3 mM Mg-GTPS; Neo, 500 M 
neomycin; and Apy, 20 U/ml apyrase. The pellet was analyzed as before. (D) Priming is essential to create a Vam7 binding site. Wild-type 
vacuoles were primed on ice for 30 min in the absence or presence of antibodies to Sec17p (200 g/ml), then reisolated and incubated with 
Vam7-HA containing supernatant generated in a parallel incubation, and processed as in the legend to Fig. 1 C. Immunoblots were decorated 
with antibodies to Pho8p to show equal amount of vacuole membranes in each lane. (E) Lipid and protein requirements for Vam7p recruitment. 
Acceptor vacuoles (12 g) were primed on ice and resuspended in PS buffer with 150 mM KCl. Trypsin (Try; 10 g/ml) was added either 
alone or in the presence of soybean trypsin inhibitor (STI; 100 g/ml) and incubated with vacuoles for 30 min on ice. STI was then added to 
stop the digestion. One aliquot was incubated with 2.5 U/ml of the phosphoinositide-specific PLC (Sigma-Aldrich) to remove inositol head 
groups. Vacuoles were reisolated and used as acceptor membranes as before. Immunoblots were decorated with anti-Pho8p to show equal 
loading. Note that trypsin digestion caused a truncation of the cytoplasmic tail of Pho8p.
 84 The Journal of Cell Biology 
 
|
 
 
 
Volume 157, Number 1, 2002
 
removed the inositol head groups from all PIPs (Mayer et al.,
2000), abolished the recruitment of Vam7p (Fig. 3 E, lane 4).
 
An essential role of PtdIns 3-P for the recruitment
of Vam7p
 
The requirement for PtdIns suggested that Vam7p might in-
teract with lipids during the recruitment and be required as
Figure 4. Rebinding of Vam7p depends on the interaction with phosphoinositides. (A) A block of the fusion reaction by addition of the 
Vam7 PX domain. Purified Vam7p fragments were added at the indicated concentrations to fusion reactions. Abbreviations are as follows: 
PX, Vam7p (1–122); PX*, Vam7p (1–135) Y42A (Cheever et al., 2001); and cc, Vam7p (165–316). (B) Time course of PX domain inhibition. A 
35 scale fusion reaction was started in the presence of ATP at 26C. Aliquots (30 l) were removed at the indicated time, antibodies (200 
ng/l) to Sec17p, Vam3p, or Vam7p or the PX domain (15 M) were added, and samples were incubated at 26C for a total of 90 min or set 
on ice before being analyzed for fusion activity. (C) Trans-SNARE formation in the presence of the PX domain. Vacuoles from BJ3505nyv1 
and DKY6281vam3 were incubated in a 600-l reaction for 40 min at 26C in the presence of ATP, Sec18p, and CoA. Then, vacuoles were 
processed and analyzed for trans-SNARE complex formation by coimmunoprecipitation with antibodies to Vam3p as described (Ungermann 
et al., 1998b). (D) The PX domain blocks the recruitment of Vam7p. The Vam7 fragments were added to primed vacuoles before the addition 
of Vam7-HA–containing supernatant. Reactions were incubated for 60 min at 26C before being analyzed. (E) The block in fusion and Vam7p 
recruitment of Vam7p coincide. The PX domain was added to primed acceptor vacuoles at the indicated concentrations in the presence of 
ATP for 10 min. Then, recruitment of Vam7-HA was performed as described above. The immunoblot of the pellet fraction was quantified by 
laser densitometry. (F) Specific binding of the isolated PX domain. The indicated fragments (15 nM each) were added to ice-primed vacuoles. 
Incubations and processing was as in the legend to Fig. 3 A. Blots were decorated with antibodies to N- and COOH-terminal Vam7p. (G) The 
PX domain does not block the fusion step itself. Vacuoles from both tester strains were incubated in reaction buffer containing Sec18p and 
CoA in the absence or presence of 3 mM BAPTA (40 min at 26C). Inhibitors (anti-Vam3p [-V3; 200 g/ml], PX domain [PX; 15 M], and 
GTPS [2 mM]) were added before reversal of the BAPTA block by the addition of 3.5 mM CaCl2. The left two bars are reactions without 
CaCl2 addition. (H) Irreversible inhibition of fusion by the PX domain. Fusion reactions containing both tester vacuoles were incubated for 30 
min on ice in the presence of ATP. Vacuoles were separated from the supernatant by centrifugation (20,000 g, 5 min, 4C). The PX domain or 
the mutant form (10 M) was incubated for 10 min at 26C with the vacuoles. Then vacuoles were reisolated (20,000 g, 5 min, 4C) and 
resuspended in reaction buffer containing ATP, CoA (10 M), and Sec18p with 20 M of the coiled-coil domain of Vam7p (cc) without this 
addition (new) or with the supernatant that had been removed after the first incubation. Fusion was continued for 60 min at 26C, and alkaline 
phosphatase activity was determined. (I) The coiled-coil domain of Vam7p cannot rescue the vacuole fusion assay poisoned with antibodies 
to Vam7p. Pretreatment of the fusion reaction was done as in the legend to Fig. 7 A. Either a new reaction mixture containing CoA and 
Sec18p or the removed supernatant of the initial incubation was added to the vacuoles. cc indicates that 10 or 20 M of the coiled-coil 
domain of Vam7p were added to a new reaction mixture. Reactions were performed for 60 min at 26C before being assayed for fusion.
(unpublished data). These data do not exclude that the respec-
tive proteins are part of a possible binding site. However, pro-
tease pretreatment of the acceptor membrane after the ice/
ATP incubation prevented rebinding of Vam7-A (Fig. 3 E,
lane 2), indicating the role of protein in the recruitment reac-
tion. Strikingly, pretreatment of primed acceptor vacuoles
with phosphoinositol-specific PLC from Bacillus cereus, which
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a prerequisite for fusion. As mentioned before, Vam7p con-
tains a PX domain that binds specifically to PtdIns 3-P
(Cheever et al., 2001), whereas the coiled-coil domain is at
the COOH terminus. We speculated that PtdIns 3-P might
function as the acceptor site for Vam7p and would hence be
essential for vacuole fusion.
Therefore, we first analyzed whether the addition of the
purified Vam7p PX domain would influence Vam7p re-
cruitment. We purified recombinant N- and COOH-termi-
nal fragments of Vam7p and added them to the fusion reac-
tion (Fig. 4 A). Out of all of the fragments, only the native
NH2-terminal fragment inhibited fusion (Fig. 4 A), whereas
the NH2-terminal domain containing a point mutation in
the PX domain (Cheever et al., 2001) did not have any ef-
fect. We then asked at which stage the NH2 terminus would
inhibit the fusion reaction. Acquisition of resistance to in-
hibitors over a time course permits discrimination between
stages of the fusion reaction (Mayer et al., 1996). However,
this assay indicates only the last step where the respective in-
hibitor acts. For the experiment, aliquots were removed
from an ongoing fusion reaction, mixed with the indicated
inhibitor, and then incubated for the remaining time (Fig. 4
B). In addition, an aliquot was placed on ice to monitor the
extent of fusion at the time of inhibitor addition. The reac-
tion becomes resistant to inhibitors of priming like anti-
Sec17p shortly after the start of the reaction and then to
docking inhibitors like anti-Vam7p (Fig. 4 B). Inhibitors of
the fusion step inhibit with kinetics close to the ice curve.
Interestingly, the reaction was sensitive to the NH2 terminus
beyond the docking stage. Note that the antibody was raised
to the COOH-terminal 140 amino acids and therefore may
not monitor the role of the NH2 terminus precisely. This ex-
periment thus suggests that the NH2 terminus of Vam7p is
required until a late stage in the fusion reaction. We then
used established assays to analyze the effects of the NH2 ter-
minus in detail. Priming, as monitored by the ATP-depen-
dent release of Sec17p (Mayer et al., 1996), was not inhib-
ited by the addition of the NH2 terminus (unpublished
data). Furthermore, trans-SNARE complex formation, an
assay that indicates the completion of docking (Ungermann
et al., 1998b), was significantly reduced when the NH2 ter-
minus was added (Fig. 4 C). This indicates that the an-
choring of Vam7p via the NH2 terminus is required for es-
tablishing stable trans-SNARE complexes. When added to
the recruitment reaction, only the NH2-terminal peptide
blocked Vam7p rebinding from the supernatant (Fig. 4 D).
Titrating the fragments into the recruitment assay revealed
that inhibition of the Vam7 recruitment completely corre-
lated with the block in vacuole fusion (Fig. 4, A compared
with E). This indicates that the NH2 terminus specifically
inhibits the Vam7p binding site. In agreement with this,
only the native NH2 terminus was able to bind vacuoles
(Fig. 4 F). However, the NH2 terminus did not inhibit the
fusion step itself. When we incubated vacuoles from the two
tester strains in the presence of the fusion inhibitor BAPTA
and then added inhibitors before releasing the block by ad-
dition of Ca2 (Mayer et al., 1996; Eitzen et al., 2001), the
NH2 terminus did not inhibit any more (Fig. 4 G), in agree-
ment with the kinetic analysis (Fig. 6 B).
We questioned whether we could reverse the block by the
NH2 terminus (Fig. 4, H and I). Vacuoles were primed on
ice and poisoned either with the NH2 terminus or the mu-
tated version and then reisolated and supplemented with
various supernatants. Whereas the NH2 terminus firmly in-
hibited, the mutant NH2 terminus did not interfere with the
rescue of fusion by a supernatant containing released Vam7p
(Fig. 4 H). We also asked whether the COOH-terminal
coiled-coil domain is sufficient to rescue the fusion reaction
poisoned by anti-Vam7p antibodies (Fig. 4 I). Again, rescue
was possible with a supernatant containing the endogenous
Vam7p but not the COOH terminus alone. Thus, even
though the overexpressed COOH terminus is able to rescue
vacuole morphology in vivo (Cheever et al., 2001) the an-
choring of Vam7p via the NH2-terminal PX domain to vac-
uoles is necessary to guide the protein to the fusion site in
vitro.
Our data suggested that Vam7p was binding to vacuoles
via the PX domain at a PtdIns 3-P–specific site. Mayer et al.
(2000) reported previously that the PtdIns 3-kinase inhibi-
tor wortmannin inhibits PtdIns 3-P synthesis on isolated
vacuoles but does not inhibit in vitro fusion; and in agree-
ment with the results of Mayer et al. (2000), we see little or
no inhibition of fusion under similar conditions (Fig. 5 A,
lane 1). However, this type of experiment does not eliminate
Figure 5. A requirement for PtdIns 3-P for vacuole fusion and 
Vam7 rebinding. (A) Wortmannin inhibits vacuole fusion. Vacuoles 
were purified from the indicated wild-type strains and incubated in 
reaction buffer containing ATP at 26C for 90 min in the absence or 
presence of wortmannin (300 M) before being assayed for fusion. 
For each reaction, a control incubation was done without ATP, 
which was subtracted. Where indicated, wortmannin was added 
during the spheroplasting reaction before vacuole isolation (as 
described in Materials and methods). (B) Vacuoles lacking Vps34p 
do not recruit Vam7p efficiently. BJ3505 vacuoles and vps34 
vacuoles were preincubated on ice with ATP and used as acceptor 
membranes for soluble Vam7-HA as described in the legend to Fig. 3 
A. At the indicated time points, aliquots were removed and processed 
for recruitment. Analysis of bound proteins was done as before. 
Decoration of immunoblots with anti-Vti1p served as a loading control.
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PtdIns 3-P already residing on the vacuole at the time of iso-
lation. Therefore, we sought to deplete PtdIns 3-P by pre-
treating spheroplasts with wortmannin for 30 min before
vacuole purification. When only one vacuole population
(Pep4p or Pho8p deficient) was obtained from pretreated
spheroplasts, variable degrees of fusion inhibition were
noted (unpublished data). However, when both vacuole
populations were obtained from wortmannin-pretreated
spheroplasts the fusion signal was consistently inhibited by
60–80% and could be further suppressed by including the
inhibitor in the reaction buffer (Fig. 5 A). These results indi-
cate that a wortmannin target, probably the Vps34p PtdIns
3-kinase (but possibly also the PtdIns-4-kinase Stt4p [Cutler
et al., 1997]), is required to make vacuoles fusion compe-
tent. To test this possibility, we used vacuoles deleted for
VPS34 as acceptor vacuoles in the recruitment assay. To fol-
low the kinetics of the rebinding of Vam7p in the second in-
cubation, we removed aliquots at the indicated time points.
Depletion of PtdIns 3-P caused a severe reduction in the re-
cruitment of Vam7p (Fig. 5 B), and fusion of the vacuoles
was strongly reduced (unpublished data). Both results show
that Vps34p generates PtdIns 3-P as a prerequisite of effi-
cient fusion and rebinding by Vam7p from the cytosol.
To more directly target PtdIns 3-P, recombinant GST-
2xFYVE domain of the mammalian receptor tyrosine kinase
substrate Hrs (Gillooly et al., 2000) was used to selectively
block PtdIns 3-P on the vacuole membrane. FYVE domains
bind to PtdIns 3-P only (Kutateladze et al., 1999). GST-
2xFYVE inhibited in vitro fusion by 50% at 200 nM and
almost completely at 500 nM (Fig. 6 A). A mutant form of
recombinant GST-2xFYVE (C215S), which cannot bind
PtdIns 3-P, was noninhibitory even when added at 5 M
(Fig. 6 B). Both the FYVE domain and the PX domain
block the recruitment of Vam7p from the supernatant to the
vacuole membrane (Fig. 6 C), showing that PtdIns 3-P
binding is essential to maintain Vam7p on the vacuole. In
addition, kinetic staging experiments indicated that GST-
FYVE inhibits at the docking stage of fusion, whereas the
PX domain inhibits slightly later (Fig. 6 D). Although the
FYVE domain just binds PtdIns 3-P, the PX domain also
may bind proteins at the fusion site specifically, which could
explain this difference.
However, binding of Vam7p is not limited to an interac-
tion via PtdIns 3-P but must also be regulated. Therefore,
we asked which role Ypt7p has as a possible receptor site of
Vam7p. In a previous end-point analysis, Ypt7p-extraction
by Gdi1p on the acceptor membrane prevented Vam7p re-
cruitment (Fig. 3 C). However, it was possible that Vam7p
had been recruited but was released once fusion had oc-
curred. Note that fusion was partially insensitive to Gdi1p
after the initial incubation (Fig. 1 E and Fig. 2 D). There-
fore, we asked whether the block in recruitment in the pres-
ence of Gdi1p was instantaneous after removal of Ypt7p.
Vacuoles were primed on ice and then reisolated and incu-
bated in the presence of Gdi1p and soluble Vam7p. We
then monitored the rebinding of Vam7p over time. Interest-
Figure 6. Masking of PtdIns 3-P reveals a specific function of the PX domain. (A) Inhibition of fusion by the recombinant FYVE domain. 
GST-2xFYVE (as described in Materials and methods) was added at the indicated concentration to the fusion reaction. Fusion was assayed 
after 90 min at 26C. (B) Inhibition by the FYVE domain is specific. The indicated concentration of wild-type FYVE domain (1 M) or an 
inactive mutant (C215S; 5 M) was added to a fusion reaction. Alkaline phosphatase activity was determined after 90 min at 26C. (C) Both 
PX and FYVE domain block the recruitment of Vam7p. Acceptor vacuoles were preincubated on ice with ATP for 30 min, then reisolated 
(5 min, 20,000 g, 4C), and incubated with recombinant FYVE (1 M) or PX (15 M) protein. The recruitment of Vam7-HA and the analysis 
was done as described in the legend to Fig. 3. (D) Kinetic analysis of the PX and FYVE inhibition. The experiment was performed as described 
in the legend to Fig. 4 B. At the indicated time points, FYVE protein (1 M) or the PX domain (15 M) were added. (E) Binding and release of 
Vam7p from Gdi1p-treated vacuoles. Wild-type acceptor vacuoles were primed on ice, then pretreated with Gdi1p (see Fig. 5 C), resuspended 
with Vam7-HA containing supernatant, and incubated at 26C. At the indicated times, aliquots were removed and separated into pellet and 
supernatant fraction. Analysis of the pellet was done as described above.
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ingly, Vam7p was able to rebind but was lost from the mem-
brane at 60 min, the minimal time it takes to complete fu-
sion in our reaction (Fig. 6 E, lanes 2–6). In contrast,
Vam7p remained associated with the vacuoles in the absence
of Gdi1p (Fig. 6 E, lane 1). Thus, Vam7p can reassociate
with vacuoles in the absence of Ypt7p but is not maintained
there. One possibility would be that Ypt7p is necessary to
interact with Vam7p when a PtdIns 3-P site is not accessible
or not present on the vacuole. However, after one complete
fusion cycle PtdIns 3-P might be consumed due to the ac-
tion of PtdIns phosphatase or Fab1p, a PtdIns 3-P 5-kinase
(Yamamoto et al., 1995), and synthesis of PtdIns 3-P via the
PtdIns 3-kinase Vps34p might then be necessary to main-
tain a docking site for Vam7p. Future experiments will be
necessary to clarify this issue.
In sum, Vam7p rebinds to vacuoles via the PX domain.
Our data show that PtdIns 3-P plays an important role in the
assembly of Vam7p with the SNARE complex prior to fusion.
Discussion
The SNAP-23–like protein Vam7p is a mobile SNARE
Fig. 7). Vam7p is initially part of the cis-SNARE complex
and is released from the vacuoles as a monomer during
priming on ice (Fig. 1, C and D). The recruitment requires
a specific PtdIns 3-P acceptor site and occurs via the NH2-
terminal PX domain (Figs. 4, 5, and 6). Finally, the re-
leased Vam7p is functional and can rescue a fusion re-
action. Our data show that Vam7p associates with the
vacuoles via a lipid-defined acceptor site and can act as a
limiting factor for vacuole fusion controlled by the status of
lipid phosphorylation on the vacuole.
Several aspects of the fusion reaction are highlighted by
these observations. Priming on ice reveals that Vam7p,
Ykt6p, Nyv1p, and the -SNAP homologue Sec17p disas-
semble efficiently from Vam3p and Vti1p. This disassembly
does not include Vti1p and Vam3p. The dissociation of
Vam3p and Vti1p appears to require elevated temperature
but not Sec18p (unpublished data; Ungermann et al., 1999).
Therefore, we believe that priming occurs in two steps, the
ATP-dependent release of Vam7p, Sec17p, Nyv1p, and
Ykt6p, and the dissociation of the Vam3p-Vti1p complex.
The reactions may occur fast under normal conditions, but
consecutive dissociation might be needed to orchestrate de-
fined protein–protein interactions required for tethering.
The priming-dependent release of Vam7p on ice was un-
expected but is not without precedent. SNAP-23, the eu-
karyotic homologue, is recruited to secretory granules before
their exocytic fusion at the mast cell plasma membrane (Guo
et al., 1998). Interestingly, the authors take advantage of a
similar behavior, namely that SNAP-23 can be recruited
from distant sites to the vesicles before fusion, by incubating
the cells on ice with ATP. Later, it was demonstrated that
the cytoskeletal protein vimentin binds SNAP-23 and serves
as an essential pool of this SNARE (Faigle et al., 2000).
When cells are treated with the NSF inhibitor NEM,
SNAP-23 is not found in association with vimentin but is
found in association with the SNARE complex. In yeast,
Sato et al. (1998) showed that Vam7p also exists in pools in
the cytosol and on the vacuole. If the NSF homologue
Sec18p is inactivated in a temperature-sensitive mutant,
Vam7p is mostly found in association with the vacuole
membrane (Sato et al., 1998). Therefore, it was assumed
that SNARE complex disassembly and Vam7p partitioning
were connected. We were able to show the complete cycle in
a defined in vitro system. Vam7p is released from the cis-
SNARE complex during the priming reaction and is re-
cruited via PtdIns 3-P to the vacuoles as a prerequisite for ef-
ficient fusion (Figs. 1 and 2).
The released Vam7p is a functional intermediate. First,
vacuoles depleted of Vam7p in a preincubation can fuse
again if supplemented with a soluble pool of Vam7p (Fig. 2
B). Second, if vacuoles are poisoned with antibodies after the
initial priming and Vam7p release, fusion is only possible if
Vam7p is provided as a soluble pool (Fig. 2 C). Vam7p can
rescue the reaction at several points during the fusion reac-
tion. Initial data suggested that the association of Vam7p
with the Rab GTPase Ypt7p was essential for Vam7p re-
trieval on vacuoles (Ungermann et al., 2000). This was sup-
ported by the interaction of Vam7p and Ypt7p in a two-
hybrid screen (Uetz et al., 2000). A few issues are still puzzling.
First, recruitment of Vam7p is possible if Ypt7p has been re-
moved (Fig. 6 E) or blocked by antibodies (unpublished
data), though the recruited Vam7p dissociates from the vac-
uole when Ypt7p is removed from the membrane (Fig. 6 E).
Second, vacuoles lacking Ypt7p still serve as acceptor vacu-
oles, albeit with reduced efficiency (unpublished data). How-
ever, these vacuoles may still contain late endosome markers
and therefore could have other binding sites for Vam7p.
Thus, the role of Ypt7p depends on whether Vam7p is trans-
ferred directly from the SNARE complex or is recruited from
the cytosol. We do not know the basis for this difference, but
we can conclude that tethering does not depend on Vam7p,
whereas fusion does depend on Vam7p (Fig. 2, C and D).
Thus, Vam7p can enter the reaction at several stages. In this
respect, our observation is comparable to the findings of
Scheller and colleagues who were able to block exocytosis in
PC12 cells by adding botulinum toxin and rescued this block
by readdition of the removed peptide (Chen et al., 1999).
However, our rescue requires an intact protein that cycles be-
tween vacuoles and cytosol in vivo and in vitro.
Our data clearly show that PtdIns 3-P is the essential
phosphoinositide required for Vam7p binding. Most PtdIns
Figure 7. Schematic overview of Vam7p rebinding to vacuoles. 
The three basic stages of the vacuole fusion reaction and the respective 
inhibitors are shown. V7, Vam7p; PX, PX domain of Vam7p; FYVE, 
GST2xFYVE of Hrs.
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3-P is present already on the isolated vacuole, unless Vps34p
was inactivated before the vacuole purification (Fig. 5 A). It
appears though that synthesis of PtdIns 3-P is also occurring
on the vacuole, since some wild-type vacuoles are more sen-
sitive to wortmannin (Fig. 5 A). It is known that Rab pro-
teins bind a variety of effectors (Zerial and McBride, 2001).
Zerial and coworkers demonstrated that several proteins are
complexed with the Rab5 GTPase in its active GTP-bound
stage (Christoforidis et al., 1999a). The lipid kinase hVps34,
which was found in the isolate, was shown to be essential for
endosome fusion (Christoforidis et al., 1999b). Our data
show that the PtdIns 3-P is required for efficient fusion and
depends on Vps34p (Fig. 5).
We used two defined domains to map the PtdIns 3-P site
on the vacuole, the PX domain of Vam7p and the FYVE do-
main of Hrs (Gillooly et al., 2000). Both domains interact
with PtdIns-3 P and inhibit the recruitment of Vam7p simi-
larly. Interestingly, the PX domain of Vam7p inhibited the
fusion assay later than the FYVE domain does and later than
the antibody to Vam7p, which was raised to the COOH ter-
minus, not to the PX domain. How do we explain these dis-
crepancies? An antibody binds the respective antigen and in-
hibits its function. The PX domain binds PtdIns 3-P tightly
and therefore blocks the binding site for Vam7p. It may also
interact with proteins at the docking site. Although the FYVE
domain (from mammalian Hrs) can do the former, it will
most likely not bind yeast vacuole proteins in a specific man-
ner. Therefore, we conclude that the Vam7p PX domain tar-
gets Vam7p precisely to the fusion site to execute its function.
We propose that a defined lipid domain is present during
docking to allow the association of Vam7p and possibly
other factors with the vacuole. This is supported by our ob-
servations that the PX domain is essential for targeting
Vam7p to the fusion site (Fig. 4) and by the binding and re-
lease of Vam7p in the presence of Gdi1p (Fig. 6 E). Fur-
thermore, the COOH-terminal domain of Vam7p is not
sufficient to rescue the reaction, suggesting that a lipid asso-
ciation via the PX domain is a prerequisite for the migration
into the fusion site and supports our idea of a lipid domain
present at this site. It appears that this requirement can be
bypassed in vivo by the overexpression of the Vam7p coiled-
coil domain (Cheever et al., 2001). However, the strong ef-
fects observed in our defined in vitro reaction suggest that
cells have selected a more complex pathway to regulate the
fusion reaction by setting up a defined lipid domain to tar-
get a SNARE to its place of function.
Materials and methods
Reagents and strains
Chemicals were purchased from Sigma-Aldrich unless noted otherwise.
Antibodies to Vam7p were raised in White New Zealand rabbits against an
NH2-terminal (amino acid 1–122) and a GST-tagged COOH-terminal frag-
ment (amino acids 165–316) of Vam7p purified from Escherichia coli.
The yeast strains used in this study were as described (Haas et al., 1994).
The COOH-terminal tagging of Vam7p with protein A or HA was done by
transformation of PCR fragments containing the inserts and a TRP1 marker
(Knop et al., 1999). Colonies that grew on SC-trp plates were restreaked and
analyzed for a shift in the molecular weight with antibodies to Vam7p.
Biochemical techniques
GST-tagged N- (Cheever et al., 2001) and COOH-terminal fragments
(amino acid 165–316) of Vam7p were expressed in BL21 E. coli cells and
induced with 0.1 mM IPTG for 1 h in the presence of 1 mM PMSF (N-ter-
minal fragments) or with 1 mM IPTG for 3 h. Cells were harvested, soni-
cated in the presence of 50 mM Tris, pH 7.4, and 150 mM NaCl and im-
mediately purified via glutathione beads (Amersham Pharmacia Biotech).
Fragments were cleaved from the GST by thrombin, and the protease was
removed by addition of benzamidine agarose (Sigma-Aldrich). Antibodies
to Vam7p were purified on CNBr-coupled GST-Vam7p (165–316) (Mayer
et al., 1996). Recombinant mammalian Hrs GST-2xFYVE and the C215S
mutant were expressed in E. coli BL21 cells (Stratagene), from a plasmid
provided by H. Stenmark (Institute of Cancer Research, Oslo, Norway),
and enriched on glutathione-sepharose to 	90% purity as described
(Gillooly et al., 2000).
Vacuole purification and wortmannin pretreatment
Vacuoles were purified by lyticase treatment and DEAE lysis as described
(Haas et al., 1994). Wortmannin pretreatment of spheroplasts was per-
formed as follows. Wortmannin (Sigma-Aldrich) was dissolved in DMSO
immediately before use. Wortmannin (50 M final) was added to cells sus-
pended in spheroplasting buffer, and the suspension was incubated for 5
min at 30C, then oxalyticase enzyme was added, and the suspension was
incubated at 30C for additional 25 min before fractionation. Vacuoles
were obtained after this treatment at normal yield. Vam7p levels were sim-
ilar or slightly lower (
50% reduction).
Vacuole fusion assay
Vacuole fusion is measured by a biochemical complementation assay
(Wickner and Haas, 2000). Standard fusion reactions were done in reac-
tion buffer (10 mM PIPES/KOH, pH 6.8, 120 mM KCl, 5 mM MgCl2, 200
mM sorbitol) containing an ATP-regenerating system (0.5 mM ATP, 40 mM
creatine phosphate, 0.1 mg/ml creatine kinase), a protease inhibitor cock-
tail, 10 M CoA, and 1 g/ml His6-Sec18p.
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